United States· US:72426-818_29da37de-60f3-4dcc-8ccd-1b96631778bd
Nexlizet
A bempedoic acid and ezetimibe product containing bempedoic acid; ezetimibe, registered in United States by Esperion Therapeutics, Inc.. The same ATC class is registered in 10 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Bempedoic acid and ezetimibe is registered in 10 of 19 countries.
Countries holding a registration under ATC C10BA10 (bempedoic acid and ezetimibe), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Bempedoic acid and ezetimibe · ATC C10BA10
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BEMPEDOIC ACID; EZETIMIBE
- Manufacturer
- Esperion Therapeutics, Inc.
- Country
- United States (US)
- ATC code
- C10BA10
- ATC class
- Bempedoic acid and ezetimibe
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1172426-818-03
- ndc1172426-818-99
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bempedoic acid and ezetimibe in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUSTENDIDaiichi Sankyo Europe GmbH, Mnichov
- PolandNustendiDaiichi Sankyo Europe GmbH
- United KingdomNustendi 180mg/10mg tabletsPilsco Ltd
- SwitzerlandNustendi 180 mg / 10 mg, FilmtablettenDaiichi Sankyo (Schweiz) AG
- IcelandNustendiDAIICHI SANKYO EUROPE GmbH*
- NetherlandsNustendi 180 mg/10 mg filmomhulde tablettenDAIICHI SANKYO EUROPE GmbH
- SwedenNustendi 180 mg/10 mg Filmdragerad tablettDaiichi Sankyo Europe GmbH
- SpainNUSTENDI 180 mg/10 mg COMPRIMIDOS RECUBIERTOS CON PELICULADaiichi Sankyo Europe Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nustendi
- Liechtenstein · Nustendi
- Norway · Nustendi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/46e56b9b-fea0-4c60-b1fa-e4aaed29fc33 GET /v1/drugs/46e56b9b-fea0-4c60-b1fa-e4aaed29fc33?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "180; 10",
"substance": "BEMPEDOIC ACID; EZETIMIBE",
"productndc": "72426-818",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1",
"application_number": "NDA211617",
"marketing_category": "NDA"
}See everything about bempedoic acid and ezetimibe.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.